CO4900063A1 - Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 - Google Patents
Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2Info
- Publication number
- CO4900063A1 CO4900063A1 CO97040188A CO97040188A CO4900063A1 CO 4900063 A1 CO4900063 A1 CO 4900063A1 CO 97040188 A CO97040188 A CO 97040188A CO 97040188 A CO97040188 A CO 97040188A CO 4900063 A1 CO4900063 A1 CO 4900063A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- substituted
- genasa2
- piridines
- oxi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
Abstract
Un compuesto de fórmula Io una de sus sales farmacéuticamente aceptables, en donde:R1 se selecciona del grupo que consiste de(a) CH3 ,(b) NH2 ,(c) NHC(O)CF3 ,(d) NHCH3 ,Ar es fenil o piridinil mono-, di-, o tri-substituido (o el N-óxido del mismo) en el donde los substituyentes se escogen del grupo que consiste de:(a) hidrógeno,(b) halógeno,(c) alcoxi C1-6 (d) alquil C1-6 tio,(e) CN(f) alquil C1-6 ,(g) fluoroalquil C1-6 ,(h) N3 ,(i) -CO2 R3 , (j) hidroxi(k) -C(R4 )(R5 )-OH,(l) -alquil C1-6 -CO2 -R6 ,(m) fluoroalcoxi C1-6 ;R2 se escoge del grupo que consiste de:(a) halógeno(b) alcoxi C1-6 (c) alquil C1-6 tio,(d) CN(e) alquil C1-6 ,(f) fluoroalquil C1-6 ,(g) N3 ,(h) -CO2 R7 (i) hidroxi,(j) -C(R8 )(R9 )-OH,(k) - alquil C1-6 -CO2 -R10 (l) fluoroalcoxi C1-6 ,(m) NO2 ,(n) NR11 R12 , y(o) NHCOR13 ,R3 , R4 , R5 , R6 , R7 , R8 , R9 , R10 , R11 , R12 , R13 son cada uno independientemente seleccionados del grupo que consiste de:(a) hidrógeno,(b) alquil C1-6 ,o R4 y R5 , R8 y R9 , o R11 y R12 junto con el átomo al cual están unidos forman un anillo monocíclico, saturado de 3, 4, 5, 6 o 7 átomos.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2212896P | 1996-07-18 | 1996-07-18 | |
GBGB9616126.0A GB9616126D0 (en) | 1996-08-01 | 1996-08-01 | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
US2713996P | 1996-10-01 | 1996-10-01 | |
GBGB9621420.0A GB9621420D0 (en) | 1996-10-15 | 1996-10-15 | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
US4181497P | 1997-04-08 | 1997-04-08 | |
GBGB9709291.0A GB9709291D0 (en) | 1997-05-07 | 1997-05-07 | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4900063A1 true CO4900063A1 (es) | 2000-03-27 |
Family
ID=27547268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO97040188A CO4900063A1 (es) | 1996-07-18 | 1997-07-16 | Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP0912518B1 (es) |
JP (2) | JP3251945B2 (es) |
KR (1) | KR100371620B1 (es) |
CN (1) | CN1152863C (es) |
AR (1) | AR012825A1 (es) |
AT (1) | ATE249437T1 (es) |
AU (1) | AU723179B2 (es) |
BG (1) | BG64553B1 (es) |
BR (1) | BRPI9710372B8 (es) |
CA (2) | CA2412968C (es) |
CO (1) | CO4900063A1 (es) |
CY (1) | CY2409B1 (es) |
CZ (1) | CZ292843B6 (es) |
DE (1) | DE69724788T2 (es) |
DK (1) | DK0912518T3 (es) |
DZ (1) | DZ2268A1 (es) |
EA (1) | EA001444B1 (es) |
EE (1) | EE03680B1 (es) |
ES (1) | ES2205242T3 (es) |
HK (1) | HK1023767A1 (es) |
HR (1) | HRP970389B1 (es) |
HU (1) | HU227732B1 (es) |
ID (1) | ID19602A (es) |
IL (1) | IL127441A (es) |
IS (1) | IS1958B (es) |
MY (1) | MY134841A (es) |
NO (1) | NO313327B1 (es) |
NZ (1) | NZ333230A (es) |
PE (1) | PE27299A1 (es) |
PL (1) | PL187848B1 (es) |
PT (1) | PT912518E (es) |
RS (1) | RS49881B (es) |
SI (1) | SI0912518T1 (es) |
SK (1) | SK283261B6 (es) |
TR (1) | TR199900046T2 (es) |
TW (1) | TW453994B (es) |
WO (1) | WO1998003484A1 (es) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US6096753A (en) * | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
US6004960A (en) * | 1997-03-14 | 1999-12-21 | Merck Frosst Canada, Inc. | Pyridazinones as inhibitors of cyclooxygenase-2 |
ATE271547T1 (de) * | 1997-03-14 | 2004-08-15 | Merck Frosst Canada Inc | Pyridazinone als inhibitoren von cyclooxygenase-2 |
US6127545A (en) * | 1997-04-18 | 2000-10-03 | Merck & Co., Inc. | Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors |
TW492959B (en) * | 1997-04-18 | 2002-07-01 | Merck & Co Inc | Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors |
US6130334A (en) * | 1998-04-15 | 2000-10-10 | Merck & Co., Inc. | Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors |
AR017219A1 (es) | 1997-12-19 | 2001-08-22 | Smithkline Beecham Corp | Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento |
US6174901B1 (en) * | 1998-12-18 | 2001-01-16 | Amgen Inc. | Substituted pyridine and pyridazine compounds and methods of use |
CN1284945A (zh) * | 1997-12-19 | 2001-02-21 | 安姆根有限公司 | 取代的吡啶和哒嗪化合物及其药物用途 |
JP2002506024A (ja) * | 1998-03-13 | 2002-02-26 | メルク エンド カムパニー インコーポレーテッド | 急性冠動脈虚血症候群および関連状態に対する併用療法および組成物 |
US6136804A (en) | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
EA002975B1 (ru) * | 1998-04-24 | 2002-12-26 | Мерк Энд Ко., Инк. | Способ синтеза ингибиторов циклооксигеназы-2 |
US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6531488B1 (en) * | 1998-08-31 | 2003-03-11 | Merck & Co., Inc. | Method of treating neurodegenerative diseases |
ATE258055T1 (de) | 1998-11-04 | 2004-02-15 | Smithkline Beecham Corp | Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine |
US6350744B1 (en) * | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
JP2002534385A (ja) | 1999-01-08 | 2002-10-15 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
WO2000042014A2 (de) * | 1999-01-14 | 2000-07-20 | Lonza Ag | 1-(6-methylpyridin-3-yl)-2-((4-(methylsulfonyl)phenyl)ethanon und verfahren zu seiner herstellung |
KR100446324B1 (ko) | 1999-01-14 | 2004-08-30 | 론자 아게 | 1-(6-메틸피리딘-3-일)-2-[4-(메틸술포닐)페닐]에타논 및이의 제조 방법 |
US6566527B1 (en) | 1999-07-27 | 2003-05-20 | Merck & Co., Inc. | Process for preparing 1-(6-methylpyridin-3-yl)-2-[4-methylsulphonyl)-phenyl]ethanone |
ES2249309T3 (es) | 1999-11-23 | 2006-04-01 | Smithkline Beecham Corp | Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa. |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
AU1783201A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
GB9927844D0 (en) * | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
US6858631B1 (en) | 1999-11-29 | 2005-02-22 | Merck & Co., Inc. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl |
EP1248618B1 (en) | 1999-11-29 | 2006-03-22 | Merck Frosst Canada Inc. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- 2,3']bipyridinyl |
GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
US6521642B2 (en) | 2000-05-26 | 2003-02-18 | Merck & Co., Inc. | 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis |
PH12001001175B1 (en) * | 2000-05-26 | 2006-08-10 | Merck Sharp & Dohme | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis |
CN100588395C (zh) | 2000-06-13 | 2010-02-10 | Wyeth公司 | 含有环氧化酶-2抑制剂的止痛和抗炎药物 |
GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
WO2002055502A1 (en) * | 2001-01-02 | 2002-07-18 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine derivatives useful as cyclooxygenase inhibitor |
US6673818B2 (en) | 2001-04-20 | 2004-01-06 | Pharmacia Corporation | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation |
GB0112803D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112802D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
GB0112810D0 (en) | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
GB0119477D0 (en) | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
JP2006500372A (ja) | 2002-08-19 | 2006-01-05 | グラクソ グループ リミテッド | 選択的cox−2阻害物質としてのピリミジン誘導体 |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
EP1531820A1 (en) | 2002-08-30 | 2005-05-25 | Memory Pharmaceuticals Corporation | Anabaseine derivatives useful in the treatment of neurodegenerative diseases |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
CA2509605C (en) | 2002-12-13 | 2010-10-05 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
ES2214130B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 2-3'-bipiridinas. |
ES2213485B1 (es) | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | Derivados de la 2-fenilpiran-4-ona. |
AU2004237439B2 (en) | 2003-05-07 | 2009-09-10 | Osteologix A/S | Treating cartilage/bone conditions with water-soluble strontium salts |
DE10322844A1 (de) * | 2003-05-19 | 2004-12-16 | Clariant Gmbh | Verfahren zur Herstellung von Pyridin-2-boronsäureestern |
DE602005013116D1 (de) | 2004-12-23 | 2009-04-16 | Glaxo Group Ltd | Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten |
MX2007013304A (es) | 2005-04-26 | 2007-12-13 | Pfizer | Anticuerpos de p-caderina. |
JP2006306743A (ja) * | 2005-04-26 | 2006-11-09 | Hamamatsu Photonics Kk | 体液処理方法 |
PT2447283E (pt) | 2005-09-07 | 2015-10-08 | Pfizer | Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1) |
KR20090092307A (ko) | 2006-12-22 | 2009-08-31 | 레코르다티 아일랜드 리미티드 | 하요도 장애에 대한 α2δ 리간드 및 NSAIDs의 복합 치료 |
GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
PL2401253T3 (pl) | 2009-02-27 | 2016-05-31 | Cadila Healthcare Ltd | Sposób otrzymywania etorykoksybu |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
WO2011012622A1 (en) | 2009-07-30 | 2011-02-03 | Glaxo Group Limited | Benzoxazinone derivatives for the treatment of glytl mediated disorders |
WO2011023753A1 (en) | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
GB201007791D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel compounds |
GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
WO2012004677A1 (en) * | 2010-07-05 | 2012-01-12 | Actavis Group Ptc Ehf | Solid state forms of etoricoxib salts |
JP5815029B2 (ja) | 2010-07-09 | 2015-11-17 | クオンベルゲンセ プハルマセウトイカルス リミテッド | カルシウムチャネル遮断薬としてのテトラゾール化合物 |
US8933132B2 (en) | 2011-01-19 | 2015-01-13 | Convergence Pharmaceuticals Limited | Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers |
EA023286B1 (ru) | 2011-05-27 | 2016-05-31 | ФАРМА ДжРС, Д.О.О. | Способ получения полиморфной формы i эторикоксиба |
CN102952117B (zh) * | 2011-08-25 | 2014-11-26 | 青岛欧博方医药科技有限公司 | 咪唑衍生物的制备方法 |
WO2013075732A1 (en) | 2011-11-21 | 2013-05-30 | Synthon Bv | Process for making crystalline form i of etoricoxib |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
EP2601952A1 (en) | 2011-12-07 | 2013-06-12 | Zentiva, k.s. | Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
CN103204803A (zh) | 2012-01-13 | 2013-07-17 | 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 | 用于合成依托考昔的方法 |
WO2015036550A1 (en) | 2013-09-13 | 2015-03-19 | Synthon B.V. | Process for making etoricoxib |
CN104788362A (zh) * | 2014-01-21 | 2015-07-22 | 济南三元化工有限公司 | 一种依托考昔或其药学上可接受的盐的制备方法 |
GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
WO2016149126A1 (en) | 2015-03-13 | 2016-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Ltb4 inhibition to prevent and treat human lymphedema |
CN106632003B (zh) * | 2015-12-31 | 2019-02-12 | 上海博志研新药物技术有限公司 | 一种依托考昔的制备方法 |
CN106632002A (zh) * | 2016-09-28 | 2017-05-10 | 贵州大学 | 一种依托考昔及其对照品5‑氯‑3‑(4‑(甲基磺酰基)苯基)‑2,3‑联吡啶的制备工艺 |
CN107056781A (zh) * | 2017-05-18 | 2017-08-18 | 康化(上海)新药研发有限公司 | 一种(E)‑5‑甲基‑1H‑吡咯并[2,3‑b]吡啶‑3‑甲醛肟的合成方法 |
CN107286085B (zh) * | 2017-05-25 | 2020-06-16 | 华东师范大学 | 一种吡啶类衍生物及其合成方法 |
CN107556232A (zh) * | 2017-09-26 | 2018-01-09 | 江苏正大清江制药有限公司 | 一种依托考昔与盐酸形成盐的新晶型及制备方法 |
MX2020003816A (es) * | 2017-10-04 | 2020-08-13 | Japan Tobacco Inc | Compuesto de heteroarilo con contenido de nitrogeno, y su uso farmaceutico. |
CN110041253B (zh) * | 2018-01-17 | 2022-03-29 | 上海翰森生物医药科技有限公司 | 吡啶类n-氧化衍生物及其制备方法和应用 |
KR102257685B1 (ko) * | 2018-09-20 | 2021-05-31 | 성균관대학교산학협력단 | Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물 |
CN109432409A (zh) * | 2018-12-19 | 2019-03-08 | 上海康孕企业管理合伙企业(有限合伙) | 血红素在改善痛经的药物、食品及保健食品中的应用 |
WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
-
1997
- 1997-07-08 SK SK36-99A patent/SK283261B6/sk not_active IP Right Cessation
- 1997-07-08 HU HU9903974A patent/HU227732B1/hu unknown
- 1997-07-08 WO PCT/CA1997/000486 patent/WO1998003484A1/en active IP Right Grant
- 1997-07-08 CZ CZ1999130A patent/CZ292843B6/cs not_active IP Right Cessation
- 1997-07-08 PT PT97929067T patent/PT912518E/pt unknown
- 1997-07-08 JP JP50639798A patent/JP3251945B2/ja not_active Expired - Lifetime
- 1997-07-08 EA EA199900137A patent/EA001444B1/ru not_active IP Right Cessation
- 1997-07-08 EE EEP199900018A patent/EE03680B1/xx unknown
- 1997-07-08 RS YUP-591/98A patent/RS49881B/sr unknown
- 1997-07-08 NZ NZ333230A patent/NZ333230A/xx not_active IP Right Cessation
- 1997-07-08 ES ES97929067T patent/ES2205242T3/es not_active Expired - Lifetime
- 1997-07-08 IL IL12744197A patent/IL127441A/xx not_active IP Right Cessation
- 1997-07-08 DE DE69724788T patent/DE69724788T2/de not_active Expired - Lifetime
- 1997-07-08 CA CA2412968A patent/CA2412968C/en not_active Expired - Lifetime
- 1997-07-08 EP EP97929067A patent/EP0912518B1/en not_active Expired - Lifetime
- 1997-07-08 AT AT97929067T patent/ATE249437T1/de active
- 1997-07-08 DK DK97929067T patent/DK0912518T3/da active
- 1997-07-08 KR KR10-1999-7000340A patent/KR100371620B1/ko active Protection Beyond IP Right Term
- 1997-07-08 SI SI9730582T patent/SI0912518T1/xx unknown
- 1997-07-08 BR BRPI9710372A patent/BRPI9710372B8/pt not_active IP Right Cessation
- 1997-07-08 PL PL97330995A patent/PL187848B1/pl unknown
- 1997-07-08 TR TR1999/00046T patent/TR199900046T2/xx unknown
- 1997-07-08 CN CNB971963770A patent/CN1152863C/zh not_active Expired - Lifetime
- 1997-07-08 CA CA002260016A patent/CA2260016C/en not_active Expired - Lifetime
- 1997-07-08 AU AU33319/97A patent/AU723179B2/en not_active Expired
- 1997-07-09 MY MYPI97003127A patent/MY134841A/en unknown
- 1997-07-14 PE PE1997000622A patent/PE27299A1/es not_active IP Right Cessation
- 1997-07-15 TW TW086110013A patent/TW453994B/zh not_active IP Right Cessation
- 1997-07-16 ID IDP972460A patent/ID19602A/id unknown
- 1997-07-16 DZ DZ970118A patent/DZ2268A1/fr active
- 1997-07-16 CO CO97040188A patent/CO4900063A1/es unknown
- 1997-07-17 AR ARP970103217A patent/AR012825A1/es active IP Right Grant
- 1997-07-17 HR HR970389A patent/HRP970389B1/xx not_active IP Right Cessation
-
1998
- 1998-12-18 IS IS4927A patent/IS1958B/is unknown
-
1999
- 1999-01-15 NO NO990191A patent/NO313327B1/no not_active IP Right Cessation
- 1999-02-16 BG BG103179A patent/BG64553B1/bg unknown
- 1999-12-09 HK HK99105780A patent/HK1023767A1/xx not_active IP Right Cessation
-
2001
- 2001-07-10 JP JP2001209904A patent/JP4246930B2/ja not_active Expired - Lifetime
-
2004
- 2004-03-31 CY CY0400025A patent/CY2409B1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4900063A1 (es) | Piridinas substituidas como inhibidores selectivos de ciclo- oxi-genasa2 | |
ES2308299T3 (es) | Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas. | |
EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
CO5640084A2 (es) | Ligandos de receptores cannabinoides y sus usos | |
AR054081A1 (es) | Derivados de pirimidina, procesos de obtencion y composiciones farmaceuticas | |
CO5540343A2 (es) | Derivados de furano y tiofeno que activan receptores activados por el proliferador de la peroxisoma humana | |
AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
CO5680430A2 (es) | Derivados de 1-benzol-piperazina como inhibidores de la captacion de glicina para el ratamiento de psicosis | |
AR025975A1 (es) | Compuestos quimicos. | |
CO5640117A2 (es) | Derivados de 2,4-diamonopirimidina | |
AR032453A1 (es) | Derivados alquinil fenil heteroaromaticos activadores de glucoquinasa, un proceso para su preparacion, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de medicamentos | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
AR063988A1 (es) | Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
EA200970379A1 (ru) | Бициклические гетероароматические соединения | |
AR041271A1 (es) | Quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa | |
AR009938A1 (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos | |
CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
AR054102A1 (es) | Derivados de fenil-piperazina-metanona. procesos de obtencion y composiciones farmaceuticas | |
AR047958A1 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. | |
AR053453A1 (es) | Derivados de aminoalquil- y amidoalquil-benzopirano substituidos |